Eric Pfanner

1 week ago | news.bloombergtax.com | Eric Pfanner |Sonja Wind

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.

1 week ago | news.bloomberglaw.com | Eric Pfanner |Sonja Wind

Nestlé SA extended its leadership overhaul by proposing longtime Inditex SA executive Pablo Isla as its next chairman to succeed company veteran Paul Bulcke when he retires next year. The move by the Swiss owner of Nespresso coffee and Purina pet food follows the surprise ouster of CEO Mark Schneider last year. His successor, Laurent Freixe, has been trying to restore sales growth as the Swiss company confronts challenges including rising costs and trade wars.

1 week ago | bloomberglinea.com.br | Eric Pfanner |Sonja Wind |Hollie Adams

Bloomberg — A Nestlé ampliou sua reformulação da liderança ao propor Pablo Isla, executivo de longa data da Inditex, como seu próximo presidente, para suceder o veterano da empresa Paul Bulcke quando ele se aposentar no próximo ano. A medida tomada pela empresa suíça dona do café Nespresso e dos alimentos para animais de estimação Purina ocorre após a surpreendente demissão do CEO Mark Schneider no ano passado.

1 week ago | bloomberg.com | Eric Pfanner |Sonja Wind

Pablo Isla in 2024(Bloomberg) -- Nestlé SA extended its leadership overhaul by proposing longtime Inditex SA executive Pablo Isla as its next chairman to succeed company veteran Paul Bulcke when he retires next year. The move by the Swiss owner of Nespresso coffee and Purina pet food follows the surprise ouster of CEO Mark Schneider last year. His successor, Laurent Freixe, has been trying to restore sales growth as the Swiss company confronts challenges including rising costs and trade wars.

1 month ago | news.bloomberglaw.com | Eric Pfanner |Rachel Phua

Medtronic Plc plans to separate its diabetes business into a standalone company, helping the medical-devices company focus on more profitable operations as the US-China trade dispute threatens its earnings. The unit will become a new publicly traded entity, with an initial public offering the favored route, according to a statement Wednesday. Diabetes accounted for about 8% of Medtronic’s $33.5 billion revenue in the latest fiscal year.